back to Australia directory
australia clinical guidance

Chronic heart failure

A detailed Australian summary of chronic heart failure, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Confirm heart failure with clinical assessment, ECG, natriuretic peptide where appropriate and echocardiography, then document ejection-fraction phenotype and cause. Assess congestion, blood pressure, rhythm, kidney function, iron status, ischaemia, valve disease, sleep apnoea and reversible precipitating factors. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:NHFA/CSANZ heart failure

The Bottom Line

  • Confirm heart failure with clinical assessment, ECG, natriuretic peptide where appropriate and echocardiography, then document ejection-fraction phenotype and cause.
  • Assess congestion, blood pressure, rhythm, kidney function, iron status, ischaemia, valve disease, sleep apnoea and reversible precipitating factors.
  • Use loop diuretic to relieve congestion but recognize that decongestion and disease-modifying therapy have different treatment goals.
  • For reduced ejection fraction, introduce evidence-based disease-modifying medicine classes with staged titration and safety monitoring rather than relying on diuretic relief.
sources for this section:NHFA/CSANZ heart failure

Practical clinical workflow

1

Topic-specific assessment action

Confirm heart failure with clinical assessment, ECG, natriuretic peptide where appropriate and echocardiography, then document ejection-fraction phenotype and cause.
2

Topic-specific diagnostic action

For reduced ejection fraction, introduce evidence-based disease-modifying medicine classes with staged titration and safety monitoring rather than relying on diuretic relief.
3

Topic-specific management action

Provide daily-weight and symptom education, vaccination, activity or rehabilitation advice, fluid and sodium guidance, and an agreed deterioration plan.
4

Topic-specific follow-through

Check iron deficiency using heart-failure criteria and consider intravenous replacement only within the Australian specialist pathway.
sources for this section:NHFA/CSANZ heart failure

Safety boundaries and escalation

  • Escalate new rest dyspnoea, hypoxia, syncope, hypotension, rapid arrhythmia, acute chest pain, marked congestion or worsening kidney function promptly.
  • Avoid NSAIDs and review medicines that worsen fluid retention, bradycardia or kidney function during every decompensation.
sources for this section:NHFA/CSANZ heart failure

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:NHFA/CSANZ heart failure

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:NHFA/CSANZ heart failure

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. National Heart Foundation of Australia and Cardiac Society of Australia and New ZealandGuidelines for the prevention, detection and management of heart failure in Australia 2018DOI 10.1016/j.hlc.2018.06.1042 路 2018 guideline; current status checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.